SynthesisJournal of microbiology and biotechnology2026
SCFA Alterations in IBS Subtypes: Systematic Evidence and Future Prospects for Biomarker-Based Diagnosis in India.
Synthesis in Journal of microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction characterized by abdominal pain and altered bowel habits. Short-chain fatty acids (SCFAs), microbial metabolites of dietary fiber, play key roles in gut physiology and have been implicated in IBS pathogenesis. Propionate, acetate, and butyrate are of particular interest as potential biomarkers for diagnosis and subtype differentiation. A systematic search of PubMed, Web of Science, and Embase identified studies reporting fecal SCFA concentrations in IBS patients versus healthy controls (HCs). Adult cohorts diagnosed by Rome criteria, case-control or randomized designs, and sufficient SCFA data for effect size calculation were included. Data were harmonized to mean ± SD and analyzed; pooled standardized mean differences (SMDs) with 95% confidence intervals (CI) were calculated, with subgroup analyses for IBS-D and IBS-C. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS). Eleven studies met inclusion criteria. Across all IBS cohorts, propionate was significantly elevated compared to HCs, while acetate and butyrate showed no differences. In IBS-D, propionate was consistently higher. In IBS-C, total SCFAs were significantly reduced, with negligible heterogeneity. Acetate, propionate, and butyrate remained non-significant, with moderate to substantial heterogeneity. NOS assessment indicated that most studies were of good quality, with one rated moderate. This meta-analysis highlights propionate elevation as a biomarker for IBS, particularly IBS-D, and reduced total SCFAs as a distinct metabolic signature in IBS-C. Variability in individual metabolites reflects dietary and methodological influences. The absence of Indian cohorts limits generalizability; future studies integrating SCFA profiling with microbiome analysis in Indian populations are needed to validate biomarker utility and support precision management of IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.